PDT Partners LLC Has $4.21 Million Stake in Natera, Inc. $NTRA

PDT Partners LLC trimmed its position in shares of Natera, Inc. (NASDAQ:NTRA) by 2.9% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 29,765 shares of the medical research company’s stock after selling 890 shares during the period. PDT Partners LLC’s holdings in Natera were worth $4,209,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in NTRA. Stifel Financial Corp grew its holdings in shares of Natera by 157.1% during the 4th quarter. Stifel Financial Corp now owns 11,524 shares of the medical research company’s stock valued at $1,824,000 after acquiring an additional 7,041 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new position in Natera in the 4th quarter worth about $232,000. Kovitz Investment Group Partners LLC purchased a new stake in shares of Natera during the 4th quarter worth about $211,000. Beacon Pointe Advisors LLC raised its stake in shares of Natera by 10.9% during the 4th quarter. Beacon Pointe Advisors LLC now owns 3,870 shares of the medical research company’s stock worth $613,000 after purchasing an additional 379 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Natera by 2.5% during the 4th quarter. The Manufacturers Life Insurance Company now owns 69,604 shares of the medical research company’s stock valued at $11,018,000 after buying an additional 1,698 shares during the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO Steven Leonard Chapman sold 6,092 shares of the stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $139.81, for a total transaction of $851,722.52. Following the completion of the sale, the chief executive officer owned 169,400 shares in the company, valued at $23,683,814. This represents a 3.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Gail Boxer Marcus sold 4,299 shares of Natera stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $167.36, for a total value of $719,480.64. Following the completion of the transaction, the director directly owned 8,118 shares in the company, valued at approximately $1,358,628.48. This represents a 34.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 49,594 shares of company stock worth $7,312,528 over the last quarter. 5.63% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

NTRA has been the topic of a number of research reports. Evercore ISI upgraded Natera to a “strong-buy” rating and set a $170.00 price objective on the stock in a report on Monday, July 28th. Stephens reissued an “overweight” rating and issued a $183.00 target price on shares of Natera in a research report on Friday, August 15th. UBS Group raised their price target on shares of Natera from $211.00 to $218.00 and gave the company a “buy” rating in a report on Friday, May 9th. Piper Sandler reaffirmed an “overweight” rating and issued a $220.00 price objective (up previously from $210.00) on shares of Natera in a research note on Monday, August 11th. Finally, Barclays reissued an “overweight” rating and set a $210.00 target price (up from $190.00) on shares of Natera in a research report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating and seventeen have issued a Buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $193.19.

Natera Trading Up 0.2%

NASDAQ:NTRA opened at $168.25 on Monday. The firm has a market capitalization of $23.09 billion, a PE ratio of -88.09 and a beta of 1.68. Natera, Inc. has a 1 year low of $110.57 and a 1 year high of $183.00. The firm’s fifty day simple moving average is $154.40 and its 200 day simple moving average is $153.80.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The firm had revenue of $546.60 million for the quarter, compared to analyst estimates of $476.84 million. During the same period in the prior year, the firm earned ($0.30) EPS. The firm’s revenue was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. As a group, analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.